According to Sinopharm, on May 26th, The Journal of the American Medical Association (JAMA, IF45.54) published an article by Sinopharm's China National Biotec Group Company Limited (CNBG) on "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults".

The report summarizes and analyzes the results of Phase III clinical trials on the efficacy and safety of the inactivated SARS-CoV-2 vaccines of Beijing Institute of Biological Products (BIBP) and Wuhan Institute of Biological Products (WIBP), which are affiliated with CNBG, based on the results of Phase III clinical trials of China Biologics' inactivated vaccines.